Zydus Lifesciences Partners with Myriad Genetics for Cancer Tests in India
Filing Summary
Zydus Lifesciences Limited has entered into an exclusive agreement with Myriad Genetics to introduce cancer-risk assessment diagnostic tests in India. The agreement involves the launch of MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, and Prolaris® Prostate Cancer Prognostic Test. These tests are designed to assist patients and healthcare professionals in understanding cancer risks and treatment pathways. The collaboration aims to enhance precision oncology in India by providing advanced diagnostic tools to clinicians. The agreement reflects Zydus’ commitment to expanding access to precision diagnostics in the Indian healthcare market.
Zydus Lifesciences Limited has signed an exclusive agreement with Myriad Genetics to introduce cancer-risk assessment diagnostic tests in India. The agreement includes the launch of the MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, and Prolaris® Prostate Cancer Prognostic Test. These tests will be available to patients, clinicians, and healthcare systems across India, aiming to provide personalized and evidence-based cancer care.
The financial terms of the agreement between Zydus Lifesciences and Myriad Genetics have not been disclosed in the filing. The focus is on the exclusive marketing and engagement of clinicians in India for the three diagnostic platforms provided by Myriad Genetics. The collaboration is expected to enhance the availability of precision diagnostic tools in the Indian market.
The scope of the agreement involves Zydus Lifesciences exclusively marketing and creating awareness about the diagnostic tests. The MyRisk® Test is a germline multigene panel that analyzes 63 clinically significant genes to estimate lifetime cancer risk. The MyChoice® HRD Plus Test assesses genomic alterations to determine HRD status in ovarian cancer patients. The Prolaris® Test is an RNA-based gene expression test that quantifies tumor aggressiveness in prostate cancer patients. These tests are designed to provide clinicians with actionable insights for personalized treatment plans.
The collaboration between Zydus Lifesciences and Myriad Genetics is positioned within the context of increasing cancer incidence globally. The tests have been widely adopted in North America, Europe, and major global cancer centers. The introduction of these tests in India aims to empower oncologists with advanced genomic decision-support tools, enhancing the precision of cancer care in the region.
The implementation timeline for the introduction of these diagnostic tests in India has not been specified in the filing. However, the agreement signifies a strategic move by Zydus Lifesciences to expand its presence in the precision oncology market in India. The collaboration involves both companies working together to enhance clinician education and diagnostic infrastructure.
Myriad Genetics is a molecular diagnostic testing and precision medicine company focused on advancing health and well-being. The company develops molecular tests that assess disease risk and guide treatment decisions across various medical specialties. The collaboration with Zydus Lifesciences aligns with Myriad Genetics’ strategic focus on expanding precision oncology globally.
Zydus Lifesciences Limited is an innovation-led life-sciences company with a presence in pharmaceuticals and consumer wellness. The company is committed to unlocking new possibilities in life sciences through quality healthcare solutions. Zydus aims to transform lives through path-breaking discoveries and expand its footprint in the precision diagnostics market.